AAAAAA

   
Results: 1-25 | 26-50 | 51-73
Results: 1-25/73
Variceal band ligation in the management of bleeding oesophageal varices: an overview
Authors: Nevens, F Rutgeerts, P
Citation: F. Nevens et P. Rutgeerts, Variceal band ligation in the management of bleeding oesophageal varices: an overview, DIG LIVER D, 33(3), 2001, pp. 284-287
Non-variceal upper gastrointestinal bleeding
Authors: Simoens, M Rutgeerts, P
Citation: M. Simoens et P. Rutgeerts, Non-variceal upper gastrointestinal bleeding, BEST PR RES, 15(1), 2001, pp. 121-133
Understanding inflammatory bowel disease - The clinician's perspective
Authors: Rutgeerts, P Geboes, K
Citation: P. Rutgeerts et K. Geboes, Understanding inflammatory bowel disease - The clinician's perspective, EURO J SURG, 167, 2001, pp. 66-72
6-Thioguanine: A naked bullet? (or how pharmacogenomics can make old drugsbrand new)
Authors: Baert, F Rutgeerts, P
Citation: F. Baert et P. Rutgeerts, 6-Thioguanine: A naked bullet? (or how pharmacogenomics can make old drugsbrand new), INFLAMM B D, 7(3), 2001, pp. 190-191
Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: A study in IBD families
Authors: Vermeire, S Peeters, M Vlietinck, R Joossens, S Den Hond, E Bulteel, V Bossuyt, X Geypens, B Rutgeerts, P
Citation: S. Vermeire et al., Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: A study in IBD families, INFLAMM B D, 7(1), 2001, pp. 8-15
The use of budesonide in the treatment of active Crohn's disease is good clinical practice
Authors: Rutgeerts, P
Citation: P. Rutgeerts, The use of budesonide in the treatment of active Crohn's disease is good clinical practice, INFLAMM B D, 7(1), 2001, pp. 60-61
Tc-99m HMPAO white blood cell scintigraphy in the assessment of the extentand severity of an acute exacerbation of ulcerative colitis
Authors: Bennink, R Peeters, M D'Haens, G Rutgeerts, P Mortelmans, L
Citation: R. Bennink et al., Tc-99m HMPAO white blood cell scintigraphy in the assessment of the extentand severity of an acute exacerbation of ulcerative colitis, CLIN NUCL M, 26(2), 2001, pp. 99-104
Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease
Authors: Rector, A Vermeire, S Thoelen, I Keyaerts, E Struyf, F Vlietinck, R Rutgeerts, P Van Ranst, M
Citation: A. Rector et al., Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease, HUM GENET, 108(3), 2001, pp. 190-193
Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease
Authors: Carty, E Rampton, DS Schneider, H Rutgeerts, P Wright, JP
Citation: E. Carty et al., Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease, ALIM PHARM, 15(9), 2001, pp. 1323-1329
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease
Authors: Cornillie, F Shealy, D D'Haens, G Geboes, K Van Assche, G Ceuppens, J Wagner, C Schaible, T Plevy, SE Targan, SR Rutgeerts, P
Citation: F. Cornillie et al., Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease, ALIM PHARM, 15(4), 2001, pp. 463-473
Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model
Authors: Colpaert, S Liu, Z De Greef, B Rutgeerts, P Ceuppens, JL Geboes, K
Citation: S. Colpaert et al., Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model, ALIM PHARM, 15(11), 2001, pp. 1827-1836
Use of anti-tumour necrosis factor agents in inflammatory bowel disease - European guidelines for 2001-2003
Authors: Schreiber, S Campieri, M Colombel, JF van Deventer, SJH Feagan, B Fedorak, R Forbes, A Gassull, M Gendre, JP van Hogezand, RA Lofberg, R Modigliani, R Pallone, F Petritsch, W Prantera, C Rampton, D Seibold, F Vatn, M Zeitz, M Rutgeerts, P
Citation: S. Schreiber et al., Use of anti-tumour necrosis factor agents in inflammatory bowel disease - European guidelines for 2001-2003, INT J COL R, 16(1), 2001, pp. 1-11
Treatment of perianal and fistulizing Crohn's disease
Authors: Miguel, JC Cuesta, MA Rutgeerts, P Korelitz, BI Rajapakse, RO Garcia-Aguilar, J
Citation: Jc. Miguel et al., Treatment of perianal and fistulizing Crohn's disease, DRUGS TODAY, 37, 2001, pp. 149-150
Anti-TNF-alpha treatment for perianal fistulizing Crohn's disease
Authors: Rutgeerts, P
Citation: P. Rutgeerts, Anti-TNF-alpha treatment for perianal fistulizing Crohn's disease, DRUGS TODAY, 37, 2001, pp. 171-177
B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis
Authors: Liu, ZJ Geboes, K Hellings, P Maerten, P Heremans, H Vandenberghe, P Boon, L van Kooten, P Rutgeerts, P Ceuppens, JL
Citation: Zj. Liu et al., B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis, J IMMUNOL, 167(3), 2001, pp. 1830-1838
Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease
Authors: Colombel, JF Rutgeerts, P Malchow, H Jacyna, M Nielsen, OH Rask-Madsen, J Van Deventer, S Ferguson, A Desreumaux, P Forbes, A Geboes, K Melani, L Cohard, M
Citation: Jf. Colombel et al., Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease, GUT, 49(1), 2001, pp. 42-46
Little benefit from mesalazine taken prophylactically after surgery for Crohn's disease
Authors: Rutgeerts, P
Citation: P. Rutgeerts, Little benefit from mesalazine taken prophylactically after surgery for Crohn's disease, GUT, 48(4), 2001, pp. 452-453
Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease
Authors: Cortot, A Colombel, JF Rutgeerts, P Lauritsen, K Malchow, H Hamling, J Winter, T Van Gossum, A Persson, T Pettersson, E
Citation: A. Cortot et al., Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease, GUT, 48(2), 2001, pp. 186-190
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis
Authors: D'Haens, G Lemmens, L Geboes, K Vandeputte, L Van Acker, F Mortelmans, L Peeters, M Vermeire, S Penninckx, F Nevens, F Hiele, M Rutgeerts, P
Citation: G. D'Haens et al., Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis, GASTROENTY, 120(6), 2001, pp. 1323-1329
Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease
Authors: Vermeire, S Joossens, S Peeters, M Monsuur, F Marien, G Bossuyt, X Groenen, P Vlietinck, R Rutgeerts, P
Citation: S. Vermeire et al., Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease, GASTROENTY, 120(4), 2001, pp. 827-833
Evidence for inflammatory dowel disease of a susceptibility locus on the xchromosome
Authors: Vermeire, S Satsangi, J Peeters, M Parkes, M Jewell, DP Vlietinck, R Rutgeerts, P
Citation: S. Vermeire et al., Evidence for inflammatory dowel disease of a susceptibility locus on the xchromosome, GASTROENTY, 120(4), 2001, pp. 834-840
Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis
Authors: Liu, ZJ Geboes, K Heremans, H Overbergh, L Mathieu, C Rutgeerts, P Ceuppens, JL
Citation: Zj. Liu et al., Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis, EUR J IMMUN, 31(5), 2001, pp. 1550-1560
Etanercept in the treatment of active refractory Crohn's disease: A single-center pilot trial
Authors: D'Haens, G Swijsen, C Noman, M Lemmens, L Ceuppens, J Agbahiwe, H Geboes, K Rutgeerts, P
Citation: G. D'Haens et al., Etanercept in the treatment of active refractory Crohn's disease: A single-center pilot trial, AM J GASTRO, 96(9), 2001, pp. 2564-2568
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease
Authors: Peeters, M Joossens, S Vermeire, S Vlietinck, R Bossuyt, X Rutgeerts, P
Citation: M. Peeters et al., Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease, AM J GASTRO, 96(3), 2001, pp. 730-734
Biological therapies for Inflammatory bowel diseases: Are we finally goingto modify the disease course?
Authors: Rutgeerts, P
Citation: P. Rutgeerts, Biological therapies for Inflammatory bowel diseases: Are we finally goingto modify the disease course?, ACT GASTR B, 64(2), 2001, pp. 153-154
Risultati: 1-25 | 26-50 | 51-73